Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital

Chardan Capital reissued their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report issued on Tuesday,Benzinga reports. Chardan Capital currently has a $3.00 price target on the stock.

Several other equities research analysts have also issued reports on the company. Guggenheim reissued a “buy” rating and set a $12.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research reduced their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, HC Wainwright dropped their target price on Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Outlook Therapeutics Stock Down 8.6 %

Shares of OTLK stock opened at $1.71 on Tuesday. The firm has a market cap of $54.69 million, a P/E ratio of -0.19 and a beta of 0.58. The company has a 50 day moving average of $1.88 and a 200-day moving average of $4.41. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last issued its earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). As a group, equities analysts expect that Outlook Therapeutics will post -2.25 EPS for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Outlook Therapeutics by 1,329.6% in the fourth quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock worth $355,000 after purchasing an additional 174,896 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Outlook Therapeutics in the 4th quarter worth $246,000. Geode Capital Management LLC raised its stake in shares of Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock worth $1,826,000 after purchasing an additional 112,812 shares during the last quarter. Scotia Capital Inc. lifted its stake in Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock valued at $140,000 after acquiring an additional 41,023 shares during the period. Finally, XTX Topco Ltd bought a new stake in Outlook Therapeutics in the 3rd quarter worth approximately $199,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.